ACAD
37.59
-0.04
-0.11%
AEMD
1.92
+0.17
+9.41%
APRI
1.68
+0.02
+1.50%
ARNA
25.09
-0.02
-0.08%
ATEC
2.19
+0.06
+2.82%
CNAT
5.38
-0.15
-2.71%
CRXM
0.151
0.00
0.00%
CYTX
0.39
-0.02
-4.79%
DXCM
69.99
+0.49
+0.71%
GNMK
9.52
-0.04
-0.42%
HALO
16.78
+0.18
+1.08%
ILMN
201.41
+1.17
+0.58%
INNV
0.097
-0.003
-3.15315%
INO
6.15
-0.14
-2.23%
ISCO
1.85
+0.05
+2.78%
ISIS
57.56
0.00
0.00%
LGND
135.55
-0.26
-0.19%
LPTN
2.93
-2.93
-100.00%
MBVX
0.67
-0.07
-9.4730%
MEIP
2.75
+0.01
+0.36%
MNOV
6.18
+0.3
+5.10%
MRTX
9.85
-0.5
-4.83%
MSTX
0.13
-0.01
-5.28%
NBIX
58.93
+0.1
+0.17%
NUVA
54.25
-0.36
-0.66%
ONCS
0.97
-0.01
-1.01%
ONVO
1.97
-0.04
-1.99%
OREX
2.12
-0.17
-7.22%
OTIC
3.3
-0.15
-4.35%
QDEL
43.1
-0.03
-0.07%
RCPT
231.96
0.00
0.00%
RGLS
1.31
-0.01
-0.76%
RMD
77.38
+0.06
+0.08%
SCIE
0
0.00
-50.0000%
SPHS
2.25
+0.01
+0.45%
SRNE
1.8
0.00
0.00%
TROV
0.7
+0.02
+2.93%
VICL
2.41
0.00
0.00%
VOLC
18
0.00
0.00%
ZGNX
14.4
+1.35
+10.34%
ACAD
37.59
-0.04
-0.11%
AEMD
1.92
+0.17
+9.41%
APRI
1.68
+0.02
+1.50%
ARNA
25.09
-0.02
-0.08%
ATEC
2.19
+0.06
+2.82%
CNAT
5.38
-0.15
-2.71%
CRXM
0.151
0.00
0.00%
CYTX
0.39
-0.02
-4.79%
DXCM
69.99
+0.49
+0.71%
GNMK
9.52
-0.04
-0.42%
HALO
16.78
+0.18
+1.08%
ILMN
201.41
+1.17
+0.58%
INNV
0.097
-0.003
-3.15315%
INO
6.15
-0.14
-2.23%
ISCO
1.85
+0.05
+2.78%
ISIS
57.56
0.00
0.00%
LGND
135.55
-0.26
-0.19%
LPTN
2.93
-2.93
-100.00%
MBVX
0.67
-0.07
-9.4730%
MEIP
2.75
+0.01
+0.36%
MNOV
6.18
+0.3
+5.10%
MRTX
9.85
-0.5
-4.83%
MSTX
0.13
-0.01
-5.28%
NBIX
58.93
+0.1
+0.17%
NUVA
54.25
-0.36
-0.66%
ONCS
0.97
-0.01
-1.01%
ONVO
1.97
-0.04
-1.99%
OREX
2.12
-0.17
-7.22%
OTIC
3.3
-0.15
-4.35%
QDEL
43.1
-0.03
-0.07%
RCPT
231.96
0.00
0.00%
RGLS
1.31
-0.01
-0.76%
RMD
77.38
+0.06
+0.08%
SCIE
0
0.00
-50.0000%
SPHS
2.25
+0.01
+0.45%
SRNE
1.8
0.00
0.00%
TROV
0.7
+0.02
+2.93%
VICL
2.41
0.00
0.00%
VOLC
18
0.00
0.00%
ZGNX
14.4
+1.35
+10.34%
Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

HUYA Bioscience International Announces A Strategic Alliance With The Korea Drug Development Fund

November 30, 2015 – 6:35 am

SAN DIEGO, Nov. 30, 2015 /PRNewswire/ — HUYA Bioscience International, the leader in accelerating global development of China’s pharmaceutical innovations, today announced it has signed a Memorandum of Understanding with the Korea Drug Development Fund (KDDF) to foster collaboration between KDDF and HUYA with the ultimate goal of advancing Korean development and commercialization of healthcare products for the global market.

HUYA is the first company to have recognized China’s potential as an important source of new innovative preclinical and clinical stage compounds. The company advances the development and value creation for China-sourced novel biopharmaceutical compounds in worldwide markets. HUYA has already established more than 100 agreements with leading universities and research institutes throughout China as a pioneer in the licensing of both preclinical and clinical stage compounds from the country. Now the company will expand that effort to include Korea in partnership with the KDDF.

“This partnership is particularly exciting given Korea’s emerging biotechnology products coupled with HUYA’s mission and track record in bringing drug candidates from Asia for global development, said Mireille Gillings, Ph.D., CEO of HUYA. “We look forward to great success from this alliance in the coming years.” “We are very pleased about working with the KDDF adding to our activities in China and Japan” said Clem Gingras CTO and COO of Asia. “We now have strategic alliances in all three countries involved in the Tripartite Cooperation Treaty.”

KDDF’s CEO, Sang Aun Joo, M.D., Ph.D. said, “We are expecting that adding more promising drug candidates via the strategic alliance with HUYA would deliver substantial performance for Korean pharmaceutical R&D to maximize global licensing-out opportunities and to enter global new drug development arena” 

About HUYA Bioscience International
HUYA Bioscience International is the leader in enabling and accelerating the global development of novel biopharmaceutical product opportunities originating in China. HUYA has established extensive collaborations with Chinese biopharmaceutical, academic and commercial organizations to speed development and value creation in worldwide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for building and maximizing the value of biopharmaceutical innovation in China. HUYA has offices in the U.S., Japan and eight strategic locations across China, with joint headquarters in San Diego and Shanghai. With the largest team of scientists working with Chinese innovators, HUYA identifies and advances promising drug candidates globally. Earlier this year, HUYA was named the winner of a Stevie® Award in the Health Products & Services and Pharmaceuticals category in the Asia-Pacific Stevie Awards. 
www.huyabio.com

About the Korea Drug Development Fund (KDDF) 
Signaling a new change in government-funded strategy, the KDDF was established in 2011 and operates through close management of development projects, linking grant support to the achievement of milestone-based research objectives. With a budget of US$1 billion, including private matching funds, the KDDF is an unparalleled response to the clinical demands of the 21st century. This investment in the country’s future is aimed at nurturing success that is initially driven by government and then transformed into a sustainable growth engine through valued researchers and industry partners. For more information, please visit http://www.kddf.org

Contact details: 
Yiota Merianos 
HUYA Corporate Communications 
+1.858.353.1217 
ymerianos@huyabio.com

Photo – http://photos.prnewswire.com/prnh/20151129/291518

 

SOURCE HUYA Bioscience International

GenomeDx’s Decipher® Test and Decipher GRID(TM) to be Featured in Five Presentations at Society of Urologic Oncology

November 25, 2015 – 1:30 pm

SAN DIEGO, Nov. 25, 2015 /PRNewswire/ — GenomeDx Biosciences today announced that data from several of its programs will be presented at the Society of Urologic Oncology’s 16th Annual Meeting, held Dec. 2-4 in Washington, D.C. Five presentations will highlight data from the Decipher® Prostate Cancer Classifier, Decipher Genomic Resource Information Database (Decipher GRID™) and the company’s research on bladder cancer.

Wednesday, Dec. 2
Session I: 4:30 p.m. to 6 p.m. EST

Title: Validation of a Genomic Classifier for prediction of metastasis following postoperative salvage radiation therapy
Presenter: Robert Den, M.D., assistant professor of radiation oncology and cancer biology at Thomas Jefferson University
Poster Number: 74

Title: Validation of a Genomic Classifier for predicting post-prostatectomy recurrence in a community based health care setting
Poster Number: 78

Title: Efficacy of early and delayed radiation in a prostatectomy cohort adjusted for genomic and clinical risk
Presenter: Ashley Ross, M.D., Ph.D., associate professor of urology and oncology, Johns Hopkins School of Medicine
Poster Number: 106

Title: B7H3 expression is androgen related and predictive of prostate cancer outcomes in a large natural history cohort of men undergoing prostatectomy
Presenter: Ashley Ross, M.D., Ph.D., associate professor of urology and oncology, Johns Hopkins School of Medicine
Poster Number: 105

Friday, Dec. 4
Young Urologic Oncologists Program: 4:30 p.m. to 6 p.m. EST

Title: Can bladder cancer gene expression signatures be used to predict lymph node metastasis at the time of radical cystectomy?
Presenter: Roland Seiler, M.D., University of British Columbia
Presentation Number: 1

About Decipher® Prostate Cancer Classifier
Decipher® is a genomic test that provides an assessment of tumor aggressiveness and is used by radiation oncologists and urologists to determine who to treat and how to treat them in order to offer the most effective and least harmful course of therapy. Decipher offers valuable insight that is distinct from clinical measures of risk including PSA and Gleason score. Studies of thousands of patients from leading cancer centers, published in more than 20 peer-reviewed journals, demonstrate that Decipher can accurately predict metastatic disease, identify patients most likely to benefit from therapeutic intervention, and lead to significant cost-savings for healthcare systems by reducing unnecessary procedures. Decipher is covered by Medicare and multiple private insurance plans in the US representing over 190 million covered lives.

Learn more at www.DecipherTest.com 

About Decipher GRIDTM
The Decipher Genomic Resource Information Database (Decipher GRID™) is the world’s largest clinically-annotated genomic expression database in urologic cancer created to enable improvements to precision medicine in patient care. GRID unifies a patient’s whole genome data with clinical outcomes from thousands of patients evaluated with Decipher®, providing unprecedented data sharing capabilities. Ultimately, GRID will use patient tumor genomic information to better match an individual to a targeted therapy with the highest likelihood of providing a benefit. The Decipher GRID program is rapidly expanding as major cancer centers partner with GenomeDx to access the database to advance their understanding of urologic cancers through the analysis of large amounts of genomic data.

Learn more at www.DecipherGRID.com

About GenomeDx Biosciences
GenomeDx Biosciences is a genomic information company changing the landscape of urologic cancer patient care with innovative genomic solutions that empower physicians and patients to make more informed decisions about patient treatment. Using advanced cloud-based bioinformatics to mine vast amounts of genomic data, the company develops and commercializes proprietary clinical tests that provide actionable information to answer key clinical questions in patient management. GenomeDx’s Decipher® is a genomic test that provides an assessment of tumor aggressiveness and is used by urologists and radiation oncologists to determine who to treat and how to treat them in order to offer the most effective and least harmful course of therapy. In partnership with leading medical centers, GenomeDx is building Decipher GRID, the world’s largest clinically-annotated genomic expression database in urologic cancer created to enable improvements to precision medicine in patient care. GenomeDx is based in San Diego and Vancouver, British Columbia.

Learn more at www.GenomeDx.com

Media Contact:
Ian Stone
Canale Communications
619-849-5388
ian@canalecomm.com

 

SOURCE GenomeDx Biosciences

Neurocrine Biosciences to Present at the 27th Annual Piper Jaffray Healthcare Conference

November 25, 2015 – 11:00 am

Live Audio Webcast will be on December 2, 2015

SAN DIEGO, Nov. 25, 2015 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the 27th Annual Piper Jaffray Healthcare Conference in New York.

The live presentation takes place on Wednesday, December 2 at 11:00am ET (8:00am PT).  The presentation will be webcast and may be accessed on the Company’s website at http://www.neurocrine.com.  

Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders.  The Company’s two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women’s health that is partnered with AbbVie Inc., and NBI-98854, a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders.  Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company. 

Neurocrine Biosciences, Inc. news releases are available through the Company’s website via the internet at http://www.neurocrine.com.

 

SOURCE Neurocrine Biosciences, Inc.

New Bio Fund Partner Describes A16Z Investment Strategy

November 25, 2015 – 8:08 am

When Marc Andreessen and Ben Horowitz founded their namesake venture firm in 2009, they laid out a clear-but-narrow vision for investing in a new wave of Web-based innovation. Andreessen, in…

[[Click headline to continue reading.]]

Orexigen Therapeutics to Speak at the Piper Jaffray 27th Annual Healthcare Conference

November 25, 2015 – 7:00 am

SAN DIEGO, Nov. 25, 2015 /PRNewswire/ — Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will participate in a fireside chat discussion at the Piper Jaffray 27th Annual Healthcare Conference in New York. The discussion is scheduled for Wednesday, December 2, at 8:00 a.m. Eastern Time.

To listen to the live webcast or a replay of the discussion, please visit the Investors section of the Company’s website at www.orexigen.com.  A replay will be available for 14 days after the event. 

Orexigen Contact: 

Media Contact:

McDavid Stilwell 

Julie Normart

VP, Corporate Communications and Business Development

BrewLife

(858) 875-8629

(415) 946-1087

mstilwell@orexigen.com  

jnormart@brewlife.com

 

SOURCE Orexigen Therapeutics, Inc.

At Duchenne Panel, Parents Plead With Experts, FDA Decision Looms

November 24, 2015 – 8:20 pm

In one of the more dramatic biotech events in recent memory, the FDA convened an advisory panel on Tuesday to weigh the risks and benefits of a drug called drisapersen, which has the chance to be the…

[[Click headline to continue reading.]]

Halozyme Therapeutics To Present At Upcoming Healthcare Conferences

November 24, 2015 – 2:30 pm

SAN DIEGO, Nov. 24, 2015 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Piper Jaffray Healthcare Conference in New York on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT. Dr. Helen Torley, president and CEO, will provide a corporate overview.

On Tuesday, December 8, Halozyme will also present at the 26th Annual Oppenheimer Healthcare Conference in New York at 1:00 p.m. ET/10:00 a.m. PT. Jim Mazzola, vice president of corporate communication and investor relations, will provide a corporate overview.

Both presentations will be webcast through the “Investors” section of Halozyme’s corporate website at www.halozyme.com, and a recording will be made available for 90 days following each event. To access the live webcast, please log on to Halozyme’s website approximately 15 minutes prior to the presentation to register and download any necessary audio software.

About Halozyme
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme’s lead proprietary program, investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen and AbbVie for its drug delivery platform, ENHANZE, which enables biologics and small molecule compounds that are currently administered intravenously to be delivered subcutaneously. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.

Contacts:
Jim Mazzola
858-704-8122
ir@halozyme.com

 

Logo – http://photos.prnewswire.com/prnh/20100302/LA63139LOGO

 

SOURCE Halozyme Therapeutics, Inc.

Donor’s Gift Honors Wife’s Cancer Struggle, Offers Legacy for Women’s Health

November 24, 2015 – 1:27 pm

“Jena knew this technology was just around the corner.”

SAN FRANCISCO, Nov. 24, 2015 /PRNewswire/ — Thanks to a donor with a personal connection to breast cancer, Dignity Health St. Mary’s Medical Center’s Sister Diane Grassilli Center for Women’s Health now offers the most comprehensive breast imaging capabilities in San Francisco.

Donor Fred Ruhland, along with an anonymous friend, stepped forward with a gift of $617,320 that allowed the Center to purchase new equipment for Breast Digital Mammography with Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional (3-D) mammography for the detection of breast cancer tumors, represents the most advanced breast imaging that exists.

Ruhland made the gift in memory of his wife Jena, a former St. Mary’s Foundation board member who passed away in 2012 after a battling breast cancer.

“I wanted to honor Jena by helping future patients at St. Mary’s in a very tangible way,” Ruhland said. “Jena knew this technology was right around the corner and hoped that it would be part of the detection, diagnosis, and care St. Mary’s could provide for women who come to the Center.

“My second reason for supporting this effort was to give St. Mary’s a ‘leg-up’ in technology in the San Francisco medical community. I wanted state-of-the-art equipment to match the great care Jena received during her time at St. Mary’s.”

Tomosynthesis can detect breast cancer tumors more precisely than conventional mammography, and the imaging is completed in approximately 10 minutes. During the exam, an X-ray tube moves in an arc around the breast while 11 images are taken, creating 3-D images as opposed to the flat images obtained with standard two-dimensional mammography. The technology is able to detect tumors of small size, especially in women with dense breast tissue.

Other benefits include greater accuracy in pinpointing size, shape, and location of abnormalities, which results in fewer unneeded biopsies; more precise images of dense breast tissue; and increased likelihood of detecting multiple breast tumors, which can occur in 15 percent of breast cancer patients.

Patients interested in receiving a tomosynthesis mammogram do not need to wait for a physician referral. Patients can self-refer by calling 415.750.HERS (4377) or by scheduling online through InQuicker at www.dignityhealth.org/stmarys. Breast imaging services are offered through the Sister Diane Grassilli Center for Women’s Health at St. Mary’s Medical Center, which has received full accreditation as a Breast Imaging Center of Excellence by the American College of Radiology. The center has also been recognized by Healthgrades for excellence in women’s health services.

About Dignity Health St. Mary’s Medical Center 
Dignity Health St. Mary’s Medical Center is an accredited, not-for-profit community hospital that has been caring for the people of San Francisco since 1857. Located across from Golden Gate Park, it is the longest continually running hospital in San Francisco. St. Mary’s has been named a 2014 Top Performer in Key Quality Measures by The Joint Commission for excellence in patient outcomes. In both 2014 and 2015, St. Mary’s received the Distinguished Hospital Award for Clinical Excellence from Healthgrades. St. Mary’s was also recognized as one of the Top 100 Orthopedic Programs nationally by Becker’s Hospital Review and is a Certified Stroke Center by the Joint Commission. The Joint Commission also recognized St. Mary’s as a 2013 Top Performer on Key Quality Measures®. St. Mary’s state-of-the-art Cancer Center offers the full-range of oncology, radiation, and imaging services. Beyond clinical care, St. Mary’s is committed to furthering the healing ministry, and to providing high-quality, affordable healthcare to the community we serve. For more information, visit www.dignityhealth.org/stmarys.

 

SOURCE Dignity Health St. Mary’s Medical Center

Over 340 life science executives converged on Santiago de Chile for Biolatam® 2015 global life science partnering event Nov. 16-17

November 23, 2015 – 9:34 am

CARLSBAD, Calif. and SANTIAGO, Chile, Nov. 23, 2015 /PRNewswire/ — Biolatam® international life science partnering conference took place in Santiago, Chile, November 16–17 with great success. The event, produced by EBD Group and ASEBIO in collaboration with ProChile and Chile Biotech, was attended by over 340 life science dealmakers from pharma, biotech and service companies representing US, Latin American and European entities.

Biotech companies in attendance ranged in speciality area including health, biofuels, cosmetics, agrifood, and mining, and emerging medical technology companies. Also represented were established large medtech companies; venture capital, private equity, institutional firms and business angels; distributors and hospitals.

“We are pleased by the success of this second edition of Biolatam,” said Anna Chrisman, Group Managing Director, EBD Group. “The energy was palpable, and innumerable connections were made to propel the market, both through partnering and through networking in the exhibition and evening event. Latin America is definitely a thriving emerging market that is only expected to grow.”

“We have received many congratulations for this event, with a great interest of all participants, confirming the success of Biolatam as Latin America’s leading biotechnology event,” said Regina Revilla, Chair of ASEBIO.

Across Latin America, healthcare spending is projected to increase an average of 4.6 percent annually over 2014–2018, according to a recent Deloitte report, with pharmaceutical spending growth expected to rise an average of 6.1 percent annually. This is evidence of a growing emerging life science market, ripe for dealmaking with international companies who are actively seeking a presence in the region. Biolatam was created to foster these partnerships through dedicated one-to-one meetings facilitated by partneringONE® that could result in collaborations between companies that will fuel future growth.

The highly anticipated third edition of Biolatam will take place in San Juan, Puerto Rico, November 29–30, 2016.

Additional links and information:

Follow Biolatam 2015 on Twitter:  @EBDGroup (hashtag: #BLT15) and @BIOLATAM.

About  EBD Group

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:

  • BIO-Europe® and BIO-Europe Spring®, Europe’s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
  • BioPharm America™, the fastest growing partnering event in North America
  • Biotech Showcase™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
  • BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
  • ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® Group
  • Biolatam®, facilitating partnering among global life sciences executives in Latin America’s vibrant life science hubs

EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.

EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.

EBD Group has offices in the USA and Europe.

For more information please visit www.ebdgroup.com.

About ASEBIO

The Spanish Bioindustry Association (ASEBIO), brings together 280 companies, associations, foundations, universities, research and technology centers that carry out activities directly or indirectly related to biotechnology in Spain.

Since 1999 ASEBIO has been acting as a meeting and promotion platform for those organizations interested in stimulating the national biotechnology scene.

In order to do this, ASEBIO works closely with regional, national and European governments as well as all the social organizations interested in using biotechnology to improve quality of life, the environment and generating skilled employment. ASEBIO, ranking fourth in Europe by number of members, is part of and supported by Europabio, the European Association for Bioindustries. ASEBIO is also the organizer of Biospain. (www.biospain2016.org).

For more information please visit: www.asebio.com

 

 

 

 

 

SOURCE EBD Group

Over 340 life science executives converged on Santiago de Chile for Biolatam® 2015 global life science partnering event Nov. 16-17

November 23, 2015 – 9:34 am

CARLSBAD, Calif. and SANTIAGO, Chile, Nov. 23, 2015 /PRNewswire/ — Biolatam® international life science partnering conference took place in Santiago, Chile, November 16–17 with great success. The event, produced by EBD Group and ASEBIO in collaboration with ProChile and Chile Biotech, was attended by over 340 life science dealmakers from pharma, biotech and service companies representing US, Latin American and European entities.

Biotech companies in attendance ranged in speciality area including health, biofuels, cosmetics, agrifood, and mining, and emerging medical technology companies. Also represented were established large medtech companies; venture capital, private equity, institutional firms and business angels; distributors and hospitals.

“We are pleased by the success of this second edition of Biolatam,” said Anna Chrisman, Group Managing Director, EBD Group. “The energy was palpable, and innumerable connections were made to propel the market, both through partnering and through networking in the exhibition and evening event. Latin America is definitely a thriving emerging market that is only expected to grow.”

“We have received many congratulations for this event, with a great interest of all participants, confirming the success of Biolatam as Latin America’s leading biotechnology event,” said Regina Revilla, Chair of ASEBIO.

Across Latin America, healthcare spending is projected to increase an average of 4.6 percent annually over 2014–2018, according to a recent Deloitte report, with pharmaceutical spending growth expected to rise an average of 6.1 percent annually. This is evidence of a growing emerging life science market, ripe for dealmaking with international companies who are actively seeking a presence in the region. Biolatam was created to foster these partnerships through dedicated one-to-one meetings facilitated by partneringONE® that could result in collaborations between companies that will fuel future growth.

The highly anticipated third edition of Biolatam will take place in San Juan, Puerto Rico, November 29–30, 2016.

Additional links and information:

Follow Biolatam 2015 on Twitter:  @EBDGroup (hashtag: #BLT15) and @BIOLATAM.

About  EBD Group

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:

  • BIO-Europe® and BIO-Europe Spring®, Europe’s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
  • BioPharm America™, the fastest growing partnering event in North America
  • Biotech Showcase™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
  • BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
  • ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® Group
  • Biolatam®, facilitating partnering among global life sciences executives in Latin America’s vibrant life science hubs

EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.

EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.

EBD Group has offices in the USA and Europe.

For more information please visit www.ebdgroup.com.

About ASEBIO

The Spanish Bioindustry Association (ASEBIO), brings together 280 companies, associations, foundations, universities, research and technology centers that carry out activities directly or indirectly related to biotechnology in Spain.

Since 1999 ASEBIO has been acting as a meeting and promotion platform for those organizations interested in stimulating the national biotechnology scene.

In order to do this, ASEBIO works closely with regional, national and European governments as well as all the social organizations interested in using biotechnology to improve quality of life, the environment and generating skilled employment. ASEBIO, ranking fourth in Europe by number of members, is part of and supported by Europabio, the European Association for Bioindustries. ASEBIO is also the organizer of Biospain. (www.biospain2016.org).

For more information please visit: www.asebio.com

 

 

 

 

 

SOURCE EBD Group